Patents
US 9375402 B2: Oral formulations of kinase inhibitors
- Granted
- 2016-06-28
- Filed
- 2013-08-14 application 13967270
- Type
- Utility · 4 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.
Source: PVGPATDIS, file of 2026-04-10 (ipg160628.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Verastem, Inc. 13 patents | US company or organization | Needham, MA | Verastem, Inc. Form D issuer EXACT high confidence: identical full name and state VERASTEM, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Andrew Xian Chen | San Diego, CA | 30 | PVGPATDIS, file of 2026-04-10 | |
| Yali Jennifer Tsai | Village of La Jolla, CA | 2 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K9/107 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P19/02 | PVGPATDIS, file of 2026-04-10 |
| C07D | Heterocyclic compounds | C07D213/74 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2016-05-25 | Assignment Assignment of assignor's interest | PONIARD PHARMACEUTICALS, INC. signed 2013-08-29 | ENCARTA, INC. SAN FRANCISCO, CA | 38811/188 | ECORSEXC, file of 2026-09-25 |
| 2016-05-25 | Assignment Assignment of assignor's interest | ENCARTA, INC. signed 2014-02-19 | VERASTEM, INC. CAMBRIDGE, MA | 38719/329 | ECORSEXC, file of 2026-09-25 |
| 2014-02-28 | Assignment Assignment of assignor's interest | CHEN, ANDREW XIAN signed 2010-07-21 TSAI, YALI J. signed 2010-07-21 | PONIARD PHARMACEUTICALS, INC SEATTLE, WA | 32320/401 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.